Day One Biopharmaceuticals Inc
Aperta
SettoreSettore sanitario
21.45
Panoramica
Variazione del prezzo dell'azione
24h
Minimo
Massimo
Entrata | -1.6M -21M |
|---|---|
Vendite | 14M 54M |
Margine di Profitto | -39.611 |
Dipendenti | 178 |
EBITDA | -7.7M -26M |
Raccomandazioni | Neutrale |
|---|---|
Previsioni per 12 mesi | -3.62% downside |
Capitalizzazione di Mercato | 1B 2.2B |
|---|---|
Apertura precedente | 21.45 |
Chiusura precedente | 21.45 |
Notizie sul Sentiment di mercato
By Acuity
50%
50%
162 / 342 Classifica in Healthcare
Day One Biopharmaceuticals Inc Grafico
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
Chi Siamo Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.